Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brevianamide F SCHEMBL30020520 | 1.00 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Brevianamide F SCHEMBL2039877 | 1.00 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19078569 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20900999 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19078561 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24254067 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20900998 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20901005 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20901017 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20901025 | 0.94 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058831-A1 | LEARNING MOTIVATION IMPROVERS | SUNTORY HOLDINGS LIMITED (JP) | 2016-03-03 | — | — | US | claimed |
| US-9623073-B2 | Learning motivation improvers | SUNTORY HOLDINGS LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160058831-A1 | LEARNING MOTIVATION IMPROVERS | SUNTORY HOLDINGS LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| CN-102665717-B | Learning motivation improvers | SUNTORY HOLDINGS LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-20130331344-A1 | LEARNING MOTIVATION IMPROVERS | CEREBOS PACIFIC LIMITED (SG) | 2013-12-12 | — | — | US | disclosed |
| US-20120283178-A1 | LEARNING MOTIVATION IMPROVERS | CEREBOS PACIFIC LIMITED (SG) | 2012-11-08 | — | — | US | disclosed |
| CN-102665717-A | Learning motivation improvers | SUNTORY HOLDINGS LTD | 2012-09-12 | — | — | CN | disclosed |
| US-8044103-B2 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044103-B2 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011077760-A1 | LEARNING MOTIVATION IMPROVERS | SUNTORY HOLDINGS LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | BDNF, PMP22, ADAM17 | HDAC3 1453/4885HDAC4 937/4885HDAC1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.